Anzeige
Mehr »
Dienstag, 01.07.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Dow Jones News
442 Leser
Artikel bewerten:
(2)

TodayIR: Dr. Joern S. Joergensen was elected as a member of the International Intra-Ocular Implant Club (IIIC)

DJ EQS-News: Dr. Joern S. Joergensen was elected as a member of the International Intra-Ocular Implant Club (IIIC)

EQS-News / 08/10/2020 / 10:01 UTC+8 
 
                                                               Press Release 
 
        Dr. Joern S. Joergensen was elected as a member of the International 
                                            Intra-Ocular Implant Club (IIIC) 
 
 EuroEyes (1846.HK) is proud to announce that Its founder and CEO, Dr. Joern 
    S. Joergensen, was elected as a member of the International Intra-Ocular 
   Implant Club (IIIC) during the annual meeting of IIIC on October 4, 2020. 
 
 The International Intra-Ocular Implant Club (IIIC) was founded in London in 
 1966 by Sir Harold Ridley. Dr. Ridley was the first to successfully implant 
   an artificial lens inside the human eye in 1950. His brilliant ideas were 
 not cherished by his colleagues for many years, but Dr. Ridley would not be 
    deterred and lived to see the tremendous success of the procedure he had 
         pioneered. In 2000, he was knighted by the Queen of England. Today, 
     intraocular lens implantation is the most frequently performed surgical 
        procedure worldwide and has saved countless numbers of patients from 
                                                                  blindness. 
 
   Sir Ridley founded the International Intra-Ocular Implant Club to promote 
    research and collaboration in the field of intraocular lens implantation 
       worldwide; encourage the free and unhindered global exchange of ideas 
 concerning intraocular lens implantation; provide an international forum to 
advance the understanding of intraocular lens implantation; globally promote 
    intraocular lens implantation surgery and standardization of quality and 
        availability; raise awareness of implantology globally among medical 
        providers and the public; and to sponsor and advise related national 
                                                  societies as they develop. 
 
Membership to the International Intra-Ocular Implant Club is restricted to a 
   total of 250 active members worldwide. EuroEyes is proud to announce that 
                             Dr. Joergensen was elected as an active member. 
 
    Dr. Joergensen is a true pioneer of cataract surgery and refractive lens 
  surgery. He introduced ambulatory cataract surgery in Hamburg, Germany, as 
   early as 1990 on a large scale. He also is a pioneer of LASIK surgery and 
  started to use LASIK in 1994, long before it became mainstream surgery. He 
      was among the first to adopt multifocal IOLs as a routine treatment of 
     presbyopia and has for many years implanted the largest number of Zeiss 
trifocal IOLs worldwide. Dr. Joergensen was also a very early adaptor of the 
   Visian ICL, an intraocular lens that corrects high myopia. Dr. Joergensen 
       founded EuroEyes in 1994. EuroEyes went public on the Hong Kong Stock 
        Exchange in October 2019 and currently operates 27 centers worldwide 
                                        (Germany: 15; China: 7; Denmark: 5). 
 
                   About EuroEyes International Eye Clinic Limited (1846.HK) 
 
    EuroEyes was established in 1993 and is one of the leading brands in the 
vision correction industry that combines German ophthalmology excellence and 
27 years of experience with individualised customer-care. EuroEyes is one of 
   the few eye clinic groups with a far-reaching geographical coverage, with 
   operations in Germany, Denmark and the PRC. The Group's vision correction 
   services include (i) refractive laser surgery (which includes ReLEx SMILE 
and FemtoLASIK); (ii) phakic lens (ICL) surgery; (iii) lens exchange surgery 
  (which includes the monofocal and trifocal lens exchange surgery) and (iv) 
                     others (which include PRK/LASEK and ICRS implantation). 
 
File: Dr. Joern S. Joergensen was elected as a member of the International 
Intra-Ocular Implant Club (IIIC) [1] 
 
08/10/2020 Dissemination of a Financial Press Release, transmitted by EQS 
Group. 
The issuer is solely responsible for the content of this announcement. 
 
Media archive at www.todayir.com 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=f77bdf78f6f7811c72e78d2c3aa88405&application_id=1139550&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

October 07, 2020 22:01 ET (02:01 GMT)

© 2020 Dow Jones News
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.